Pegylated interferon reduces relapses following bepirovirsen treatment in participants with chronic hepatitis B virus infection on nucleos(t)ide analogs: end of study results from the Phase 2b B-Together study

Conference Reports for NATAP

AASLD
The Liver Meeting
November Fri, Nov 10, 2023 - Mon, Nov 14, 2023


Pegylated interferon reduces relapses following bepirovirsen treatment in participants with chronic hepatitis B virus infection on nucleos(t)ide analogs: end of study results from the Phase 2b B-Together study

	AASLD 2023 Nov 19-14 https://www.aasld.org/the-liver-meeting